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Association Between Radiomics 
signature and Disease-Free 
survival in Conventional papillary 
thyroid Carcinoma
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Jung Hyun Yoon1 & Jin Young Kwak1
Patients with papillary thyroid carcinoma (PTC) would benefit from risk stratification tools that 
can aid in planning personalized treatment and follow-up. The aim of this study was to develop a 
conventional ultrasound (US)-based radiomics signature to estimate disease-free survival (DFS) in 
patients with conventional PTC. Imaging features were extracted from the pretreatment US images of 
768 patients with conventional PTC who were treated between January 2004 and February 2006. The 
median follow-up period was 117.3 months, with 85 (11.1%) events. A radiomics signature (Rad-score) 
was generated by using the least absolute shrinkage and selection operator (LASSO) method in Cox 
regression. The Rad-score was significantly associated with DFS (hazard ratio [HR], 3.087; P < 0.001), 
independent of clinicopathologic risk factors. A radiomics model which incorporated the Rad-score 
demonstrated better performance in the estimation of DFS (C-index: 0.777; 95% confidence interval 
[CI]: 0.735, 0.829) than the clinicopathologic model (C-index: 0.721; 95% CI: 0.675, 0.780). In conclusion, 
radiomics features from pretreatment US may be potential imaging biomarkers for risk stratification in 
patients with conventional ptC.
Papillary thyroid carcinoma (PTC) is the most common histologic type of thyroid cancer, and accounts for the 
majority of increased incidence in thyroid cancer during the last several decades1,2. Because of its treatability and 
relatively favorable survival rate, the perception of thyroid cancer as a “good cancer” has spread among patients 
and healthcare providers3,4. Along with recent guidelines recommending active surveillance rather than treat-
ment in selected patients, some researchers have also suggested expanding this management approach to a larger 
size range of PTCs5. However, a small subset of PTCs shows aggressive clinical behavior, with approximately 
9.1–13.3% of patients experiencing recurrence and 1.4–5.2% dying from thyroid cancer6,7. Incidence-based mor-
tality for PTC has also increased — increasing 1.1% per year overall and 2.9% per year for distant stage PTC in the 
United States2. Therefore, patients with PTC would largely benefit from preoperative risk stratification tools that 
can aid in planning appropriate treatment and follow-up.
The field of medical image analysis has grown exponentially in the past decade, fueled by the routine use of 
digital medical images and developments in methods for quantitative image analysis. Radiomics, a promising 
field in cancer imaging research, is based on the concept that medical images contain crucial information reflect-
ing underlying pathophysiology, which can be used to support evidence-based clinical decisions8. Biomarkers 
based on quantitative radiomics features have been associated with clinical prognosis and genomic phenotypes 
across a wide range of cancer types9–13. Recently, this approach has also been applied to the analysis of thyroid 
nodules. Previous studies have reported that sonographic histogram and texture analyses are useful for differenti-
ating benign and malignant thyroid nodules14–18. However, to our knowledge, there are no published studies that 
have investigated whether a radiomics approach can be used to estimate the prognosis of PTC.
Therefore, the aim of this study was to develop a radiomics signature based on thyroid ultrasound (US) images 
to estimate disease-free survival (DFS) in patients with conventional PTC, and to assess its incremental value to 
clinical-pathologic risk factors.
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Results
Clinical Characteristics and patient outcomes. Among the 768 patients, 747 (97.3%) underwent total 
or near-total thyroidectomy, 13 (1.7%) underwent hemithyroidectomy, and 8 (1.0%) underwent hemithyroidec-
tomy with contralateral subtotal thyroidectomy. Table 1 shows the clinicopathologic features of the 768 patients. 
The median follow-up period was 117.3 months (range, 36.3–154.23 months). At the last follow-up, 85 patients 
(11.1%) experienced recurrent or persistent disease, with 56 (7.3%) experiencing recurrence and 29 (3.8%) expe-
riencing persistent disease.
Construction of the Radiomics Signature. Of the 730 texture features, the top 40 features were selected 
in the LASSO Cox regression model based on repeated 10-fold cross-validation. These features were used to 
build the radiomics signature. The Rad-score calculation formula is presented in the Supplementary Information, 
where the selected features are presented.
Association of the Radiomics Signature with Disease-free Survival. At univariate analysis, the 
radiomics signature was associated with disease-free survival (HR = 4.531, 95% CI: 2.909, 7.056 [P < 0.001]) 
(Table 2). Among clinicopathologic variables, a larger pathological tumor size (HR = 1.042, 95% CI: 1.022, 1.063 
[P < 0.001]), presence of cervical lymph node metastasis (HR = 4.919, 95% CI: 2.611, 9.267 [P < 0.001]), distant 
metastasis (HR = 8.132, 95% CI: 3.286, 20.120 [P < 0.001]), gross extrathyroidal extension (HR = 2.253, 95% CI: 
1.040, 4.884 [P = 0.040]), and a higher dose of radioactive ablation (RAI) (HR = 1.010, 95% CI: 1.006, 1.013 
[P < 0.001]) was associated with worse disease-free survival.
At multivariate analysis, the radiomics signature was independently associated with disease-free survival 
(HR = 3.087, 95% CI: 1.931, 4.935 [P < 0.001]). Among clinicopathologic variables, the presence of cervical 
lymph node metastasis (HR = 3.585, 95% CI: 1.849, 6.952 [P < 0.001]), distant metastasis (HR = 3.449, 95% CI: 
1.329, 8.950 [P = 0.011]), and a higher dose of RAI ablation (HR = 1.005, 95% CI: 1.001, 1.009 [P = 0.009]) was 
associated with worse disease-free survival.
Assessment of the Incremental Value of the Radiomics Signature in DFS prediction. The clin-
icopathologic model for predicting disease-free survival yielded a C-index of 0.721 (95% CI: 0.675, 0.780). We 
created a radiomics model that integrated the radiomics signature with all clinicopathologic data, and found that 
adding the radiomics signature to the clinicopathologic model yielded an improvement of 0.056 (95% CI: 0.023, 
0.096) in the C-index, showing improved classification accuracy for disease-free survival (Table 3).
Discussion
In the current study, we evaluated the ability of multi-feature-based radiomics to help estimate disease-free 
survival in patients with conventional PTC. To our knowledge, this is the first study to apply radiomics in the 
estimation of prognosis in patients with PTC. The radiomics signature was identified as an independent prognos-
tic factor, and added incremental value to other clinico-pathologic risk factors when estimating individualized 
disease-free survival. Our study demonstrates the potential of applying a radiomics approach to conventional 
PTC.
As PTC is generally associated with an excellent long-term mortality, setting disease-free survival from 
recurrence or persistent disease as the focus endpoint for risk stratification, rather than mortality, would ben-
efit more patients by potentially aiding in individualized treatment and management. In efforts to achieve such 
Characteristics Values
Age: n (%)
  <55 years 592 (77.1%)
  ≥55 years 176 (22.9%)
Sex: n (%)
  Female 648 (84.4%)
  Male 120 (15.6%)
Pathological tumor size, mm: median (range) 16 (2–65)
Cervical lymph node metastasis (LNM): n (%)
  Absent 311 (40.5%)
  Present 457 (59.5%)
Gross extrathyroidal extension: n (%)
  Absent 33 (4.3%)
  Present 735 (95.7%)
131I dose, mCi: median (range) 30 (0–200)
Distant metastasis: n (%)
  No 757 (98.8%)
  Yes 9 (1.2%)
Table 1. Patient characteristics and pathologic features of the 768 patients with conventional papillary thyroid 
carcinoma.
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risk-stratification, previous researchers have focused on identifying clinico-pathologic risk factors associated with 
recurrent or persistent disease19–22. Yet, these studies generally included various histologic subtypes and used 
conventional risk factors which are only obtainable after treatment is completed. In our study, we found that the 
radiomics signature, which is obtained from preoperative images, was independently associated with disease-free 
survival (HR = 3.087) and could provide more prognostic information prior to the initiation of treatment.
Although radiomics has shown potential in other cancers, research in thyroid cancer has been relatively 
limited. Previous studies on radiomics in thyroid disease have mostly focused on differentiating benign and 
malignant nodules or detecting lymph node metastasis by using relatively simple histogram and texture analysis 
techniques14–16,18,23. In our study, for the construction of the radiomics signature, 730 candidate radomics features 
Variables
Hazard 
Ratio 95% CI P value
Age
  <55 years 1
  ≥55 years 1.354 0.844, 2.172 0.208
Sex
  Female 1
  Male 1.479 0.879, 2.489 0.14
Pathological tumor size, mm 1.042 1.022, 1.063 <0.001
Cervical LNM
  Absent 1
  Present 4.919 2.611, 9.267 <0.001
Gross extrathyroidal extension
  Absent 1
  Present 2.253 1.04, 4.884 0.040
Distant metastasis
  No 1
  Yes 8.132 3.286, 20.12 <0.001
131I dose 1.010 1.006, 1.013 <0.001
Rad-score 4.531 2.909, 7.056 <0.001
Table 2. Univariate analysis between variables and disease-free survival.
Variables
Clinicopathologic model
Radiomics model* = Clinicopathologic 
data + radiomics signature
HR 95% CI P value HR 95% CI P value
Age, years
  <55 1 1
  ≥55 1.669 1.0296, 2.706 0.0377 1.495 0.921, 2.426 0.104
Sex
  Female 1 1
  Male 1.205 0.6969, 2.084 0.5043 1.054 0.608, 1.829 0.851
Pathological tumor size, mm 1.027 1.0053, 1.049 0.0145 1.012 0.989, 1.036 0.301
Cervical LNM
  Absent 1 1
  Present 3.826 1.9727, 7.419 <0.0001 3.585 1.849, 6.952 <0.001
Gross extrathyroidal extension
  Absent 1 1
  Present 1.399 0.6248, 3.132 0.4144 1.145 0.497, 2.638 0.750
Distant metastasis
  No 1 1
  Yes 5.78 2.2487, 14.858 0.0003 3.449 1.329, 8.950 0.011
RAI dose 1.005 1.0016, 1.009 0.0047 1.005 1.001, 1.009 0.009
Rad-score 3.087 1.931, 4.935 <0.001
C-index (95% CI)† (0.675, 0.780) 0.777 (0.735, 0.829)
Table 3. Performance of the clinicopathologic model and radiomics model. *The radiomics model 
integrated the radiomics signature (Rad-score) with clinicopathologic data. †Difference between the two 
c-indexes = 0.777−0.721 = 0.056 (bootstrapped 95% CI: 0.023, 0.096).
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were reduced to 40 potential predictors through the LASSO cox regression model, which is known as a useful 
method for feature selection in high-dimensional data13,24. Whereas previous staging systems and nomograms, 
including the American Joint Committee on Cancer (AJC) tumor node metastasis (TNM) staging system, have 
shown excellent discriminatory ability for mortality prediction with AUC values of 0.89–0.98, the AUC values of 
nomograms for recurrence prediction in thyroid cancer have been slightly lower, ranging from 0.72–0.7619,25–29. 
In our study, the radiomics signature that combined multiple individual imaging features significantly improved 
the predictive accuracy of the clinicopathologic model, yielding a C-index of 0.777 (95% CI: 0.735, 0.829). Our 
study suggests that combining radomics data with other clinicopathologic risk factors may increase the power of 
decision support models, and aid in achieving personalized estimation of disease-free survival in PTC.
There are some limitations to this study, such as the retrospective nature of its data collection and the rela-
tively small sample size. Another limitation is the lack of external validation and a separate validation data set. 
Therefore, further studies are needed to overcome these limitations and to validate our results for better gener-
alization. Although the prospective cohort study design would be the preferred study design of such research, 
the long wait required to analyze survival outcome in PTC, due to its generally excellent prognosis, makes such 
research daunting to perform. In addition, the small number of events makes it difficult to yield reliable results 
with smaller data sets. Although we were unable to perform such an independent validation, to our knowledge, 
this is the first study to apply multi-feature-based radiomics in the estimation of prognosis in patients with PTC. 
Our results indicate that radiomics has the potential to be a tool for risk stratification, but further validation is 
needed.
In conclusion, our preliminary study shows that the identified radiomics signature has the potential to be used 
as a biomarker for risk stratification in patients with conventional PTC. The radiomics model, which incorporated 
the radiomics signature with clinicopathologic data, showed a significant improvement in discrimination perfor-
mance for evaluating disease-free survival. Although promising, these are preliminary results and further valida-
tion is required on a larger and independent data set before clinical application. After validation, the radiomics 
signature may serve as a potential tool to guide individualized management for patients with PTC, of whom the 
majority will have excellent prognosis.
Methods
patients. The institutional review board of Severance hospital approved this retrospective study and the 
requirement for informed consent was waived. Our institutional database was reviewed to identify patients with 
histologically confirmed conventional papillary thyroid carcinoma who underwent preoperative US and thyroid 
surgery from January 2004 to February 2006. In total, 768 patients were identified (648 women and 120 men; 
median age, 45 years [range, 17–80 years]; tumor size, 16 mm [range, 2–65 mm]) and comprised our study pop-
ulation. Among the study patients, 299 patients were included in a prior study which compared the diagnostic 
accuracy of preoperative staging using US imaging and CT30, and 469 patients were included in a prior study 
which investigated whether conventional US features were associated with tumor recurrence in PTC31.
surgery and Follow-up. Total or near-total thyroidectomy was performed in patients who had multiple 
tumors, extrathyroidal invasion or lymph node metastasis (LNM) on either preoperative or intraoperative find-
ings. Central compartment neck dissection including the paratracheal, pretracheal, and prelaryngeal lymph 
nodes is routinely performed at our institution. Bilateral central compartment neck dissection was performed 
in patients who underwent total or near-total thyroidectomy and ipsilateral central compartment neck dissec-
tion was performed in patients who underwent hemithyroidectomy. Lateral compartment neck dissection was 
performed in selected patients with lateral LNM diagnosed by preoperative US-guided fine-needle aspiration. If 
suspicious LNs were found during surgery, intraoperative frozen biopsy was performed. In patients confirmed to 
have lateral LNM, lateral neck compartments including levels 2, 3, 4 and anterior level 5 were dissected.
For postoperative follow-up, clinical examination, neck US, chest radiographs, and measurements of serum 
thyroid-stimulating hormone (TSH), free T4, thyroglobulin (Tg), and anti-Tg antibody were recommended 
annually. For patients with suspected recurrence chest computed tomography (CT), magnetic resonance imaging 
(MRI), whole body bone scan or fluorodeoxyglucose positron emission tomography (PET) was performed at the 
discretion of the physician.
Clinicopathologic data including age, gender, pathological tumor size, cervical lymph node metastasis (LNM), 
gross extrathyroidal extension, surgery method (total or near-total thyroidectomy, hemithyroidectomy, and 
hemithyroidectomy with contralateral subtotal thyroidectomy), and radioiodine ablation dose were collected 
from medical records. Medical records and imaging studies during postoperative surveillance were reviewed for 
patient outcome.
No evidence of disease was defined as no biochemical (suppressed thyroglobulin (Tg) < 1 ng/mL, stimu-
lated Tg < 2 ng/mL, with negative anti-Tg antibodies) or structural recurrences (no evidence of disease on US, 
cross-sectional and/or nuclear imaging) during follow-up32. Distant metastasis was defined as the development 
of thyroid cancer foci at distant organs located in areas other than the neck, which was either confirmed with 
biopsy or clinically suspected based on various imaging studies. Recurrence/persistence of disease was defined by 
biochemical, structural or functional evidence of disease that was detected with/without a period of any evidence 
of disease since initial surgery32. Disease-free survival was defined as the time of interval (in months) between 
initial surgery and occurrence of recurrence/persistence or the date of last clinical follow-up.
US Examinations. All patients underwent preoperative US including both thyroid glands and cervical 
regions, performed by using a 7–12-MHz (HDI 3000 or 5000; Philips Medical Systems, Bothell,Wash), 5–13-MHz 
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(SONOLINE Antares; Siemens Medical Solutions, Erlangen,Germany/Acuson Sequoia 512; Acuson, Mountain 
View, CA), or a 5–12-MHz linear array transducer (iU22; Philips Medical Systems, Bothell,Wash).
Radiomics Feature Analysis. For image feature extraction, a representative US image was selected for 
each tumor from images that were previously captured by the radiologist at the time of the US examination, and 
which were retrieved from the picture archiving and communication system. Manual segmentation of the thyroid 
tumors was performed by a radiologist (V. Y. P) who had 7 years of experience in thyroid US imaging. A region of 
interest (ROI) was delineated around the boundary of the index tumor on a representative US image, which was 
validated by a senior radiologist (K.J.Y) who had 16 years of experience in thyroid US imaging.
The radiomics feature extraction methodology is described in Appendix E1 (online). Texture feature extrac-
tion was performed by in-house texture analysis algorithms implemented in MATLAB 2016b (The MathWorks, 
Inc., Natick, Massachusetts, United States). After saving the ROI-segmented US images as JPG images, the images 
were then converted into grayscale intensity images by eliminating the hue and saturation information while 
retaining luminance. A total of 730 candidate radomics features, using GLCM and GLRLM texture matrices, 
single-level discrete 2D wavelet transform and so forth, were generated from a single US image (Fig. 1). Each 
image was normalized for direct comparison between patients.
statistical Analysis. To select radiomics features, we used the least absolute shrinkage and selection oper-
ator (LASSO) method in Cox regression to select the most useful prognostic imaging features for disease-free 
survival. The LASSO method is a penalized technique for variable selection that is suitable for the regression of 
high-dimensional data33.
In the LASSO Cox regression analysis, 10-fold cross-validation was used to avoid overfitting and to estimate 
errors of partial likelihood deviance, which is a goodness-of-fit statistic in Cox regression. Additionally, the whole 
process of partitioning and estimating through cross-validation was repeated 100 times. In each validation step, 
features were selected by using minimum criteria—i.e., optimal tuning parameter of the LASSO that minimized 
the partial likelihood deviance was selected and we took the average as the final coefficients for each feature34. A 
larger average coefficient indicates a more relevant feature. Repeated cross-validation can reduce variation caused 
by the randomness of partitioning the sample into 10-folds as well as estimates of prediction error.
A radiomics score (Rad score) was calculated for each patient as a linear combination of selected features that 
were weighted by their respective coefficients. The number of features chosen to calculate the radiomics score was 
determined by the mean number of features selected through 100 repeated cross-validation.
To estimate the association between disease-free survival and radiomics features with clinicopathologic fac-
tors, univariable and multivariable Cox proportional hazard regressions were performed. Hazard ratios with 95% 
confidence interval (CI) for each variable were estimated. To evaluate the incremental prognostic value of the 
radiomics score when added to clinicopathologic factors, Harrell’s C-index was calculated and compared using 
the bootstrap method with 1,000 resampling. The significance of the incremental values of the radiomics score 
was determined using 95% CI for the difference in C-index.
Figure 1. Example of the radiomics feature extraction. (a) Each tumor was first manually segmented on a 
representative US image (left) and subsequently, the position information of the ROI (middle) was collected 
and applied to the US image without marking the ROI itself, allowing the ROI to be extracted from the 
original US image (right). (b) Intensity histogram of the ROI image is shown. First and second order statistics 
values were calculated for each image. (c) For further feature extraction, the wavelet transform was used. For 
clearer presentation, the wavelet coefficients were scaled into a range from 0 to 255. From left to right: wavelet 
decompositions of the original image using LL, LH, HL, and HH, where L and H are low- and high-pass filters 
in the x- and y-directions, respectively.
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The statistical analysis was performed using R software, version 3.3.3 (http://www.R-project.org). The 
LASSO method and Cox regression was performed using the “glmnet” and “survival” R packages, respectively. 
Bootstrapping was implemented using the “boot” R package. P values < 0.05 indicated statistical significance.
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